skip to Main Content
Reduced Cardiovascular And Renal Events With Canaglifozin (CANVAS + CANVAS-R)
Sep 19 2017

Reduced Cardiovascular and Renal Events with Canaglifozin (CANVAS + CANVAS-R)

Journal Club

Presented by Alex Zhornitskiy, M.D.

Moderated by Vinhfield Ta, M.D.

Thank you, Alex, for a review of outcome data for one of the newest diabetes medications: canaglifozin (Invokana®).  Canaglifozin is a SGLT2 inhibitor, which decreases reabsorption of glucose in the renal tubules. Clinical Question: Among patients with DM2 at high risk…

Read more
Time-to-Furosemide Treatment And Mortality In Patients Hospitalized With Acute Heart Failure
Sep 05 2017

Time-to-Furosemide Treatment and Mortality in Patients Hospitalized with Acute Heart Failure

Journal Club

Presented by Stephanie Wang, M.D.

Moderated by Matthew McCullough, M.D.

Key Discussion Points: Early treatment of acute heart failure with loop diuretics lowers mortality despite initial mortality risk, and this treatment strategy might be even more effective in high-risk AHF patients Earlier treatment/identification of acute heart failure relied heavily on…

Read more
Einstein Choice: Rivaroxaban Or Aspirin For Extended Treatment Of Venous Thromboembolism
Jul 11 2017

Einstein Choice: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Journal Club

Presented by Fabiola Ochoa, M.D.

Clinical Question In patients who would benefit from continued anti-coagulation is treatment dose rivaroxaban vs thromboprophylactic dose as effective as aspirin for prevention of recurrent thromboembolism? Bottom Line Rivaroxaban at both treatment dose (20mg) and a thromboprophylactic dose (10mg), was…

Read more
PESIT Trial
Jun 06 2017

PESIT Trial

Journal Club

Thank you Dr. Noah Duncan for an excellent overview of the PESIT trial (Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope) Conclusions of the study: Pulmonary embolism was identified in nearly one of every 6 patients hospitalized for a…

Read more
BRIDGE TRIAL
Mar 09 2017

BRIDGE TRIAL

Journal Club

Presented by Dr. Thomas Vu

Thank you Thomas Vu for your excellent overview of the BRIDGE trial (Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation) Conclusions of the study: In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive…

Read more
Mar 09 2017

STOPAH TRIAL

Journal Club

Thank you Quynh Vu for your excellent overview of the STOPAH trial (Prednisolone or Pentoxifylline for Alcoholic Hepatitis) Conclusions of the study: Pentoxifylline did not improve survival in patients with alcoholic hepatitis Prednisolone was associated with a reduction in 28-day…

Read more
Back To Top